Literature DB >> 23784740

4-Methyl-amphetamine: a health threat for recreational amphetamine users.

P Blanckaert1, Jgc van Amsterdam, Tm Brunt, Jdj van den Berg, F Van Durme, K Maudens, Jch van Bussel.   

Abstract

4-Methylamphetamine (4-MA) was originally developed as an appetite suppressant, but development was halted due to side effects. It has recently resurfaced as a new psychoactive substance in Europe, and is mostly found together with amphetamine. Around 11.5% of tested Dutch speed samples were positive for 4-MA. In Belgium, 4-MA was also found in speed samples. In 2011 and 2012, several fatal incidents after amphetamine use were observed in Belgium, the United Kingdom and The Netherlands. In all victims, toxicological analysis confirmed the presence of 4-MA, in addition to amphetamine. The observed blood amphetamine levels were too low to be fatal. Contrary to amphetamine, which displays noradrenergic and dopaminergic activity, 4-MA also shows serotonergic activity, which may contribute to the observed toxicity. Other mechanisms of toxicity are put forward in this paper as well. To conclude, the observed toxicity is most likely the result of the combined dopaminergic activity of amphetamine and the serotonergic activity of 4-MA. In addition, the presence of 4-MA may have dampened the psychoactive effects of amphetamine by attenuation of the amphetamine-induced dopamine release, potentially inclining users to ingest higher doses of contaminated speed. Also, slower metabolism of 4-MA and its MAO-inhibiting properties can also contribute to the unusual high toxicity of 4-MA.

Entities:  

Keywords:  4-methylamphetamine; amphetamines; neuropharmacology; new psychoactive substances; toxicology

Mesh:

Substances:

Year:  2013        PMID: 23784740     DOI: 10.1177/0269881113487950

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  5 in total

1.  N-Alkylated Analogs of 4-Methylamphetamine (4-MA) Differentially Affect Monoamine Transporters and Abuse Liability.

Authors:  Ernesto Solis; John S Partilla; Farhana Sakloth; Iwona Ruchala; Kathryn L Schwienteck; Louis J De Felice; Jose M Eltit; Richard A Glennon; S Stevens Negus; Michael H Baumann
Journal:  Neuropsychopharmacology       Date:  2017-05-22       Impact factor: 7.853

2.  Abuse-related neurochemical and behavioral effects of cathinone and 4-methylcathinone stereoisomers in rats.

Authors:  Blake A Hutsell; Michael H Baumann; John S Partilla; Matthew L Banks; Rakesh Vekariya; Richard A Glennon; S Stevens Negus
Journal:  Eur Neuropsychopharmacol       Date:  2015-12-11       Impact factor: 4.600

3.  Effects of N-Alkyl-4-Methylamphetamine Optical Isomers on Plasma Membrane Monoamine Transporters and Abuse-Related Behavior.

Authors:  Umberto M Battisti; Ramsey Sitta; Alan Harris; Farhana Sakloth; Donna Walther; Iwona Ruchala; S Stevens Negus; Michael H Baumann; Richard A Glennon; Jose M Eltit
Journal:  ACS Chem Neurosci       Date:  2018-05-14       Impact factor: 4.418

4.  Functional characterization of N-octyl 4-methylamphetamine variants and related bivalent compounds at the dopamine and serotonin transporters using Ca2+ channels as sensors.

Authors:  Iwona Ruchala; Umberto M Battisti; Vy T Nguyen; Rita Yu-Tzu Chen; Richard A Glennon; Jose M Eltit
Journal:  Toxicol Appl Pharmacol       Date:  2021-03-27       Impact factor: 4.219

5.  Drug checking services for people who use drugs: a systematic review.

Authors:  Nazlee Maghsoudi; Justine Tanguay; Kristy Scarfone; Indhu Rammohan; Carolyn Ziegler; Dan Werb; Ayden I Scheim
Journal:  Addiction       Date:  2021-12-12       Impact factor: 7.256

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.